Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Mar;69(3):1493–1499. doi: 10.1128/jvi.69.3.1493-1499.1995

Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.

R F Cook 1, S L Berger 1, K E Rushlow 1, J M McManus 1, S J Cook 1, S Harrold 1, M L Raabe 1, R C Montelaro 1, C J Issel 1
PMCID: PMC188739  PMID: 7853482

Abstract

Serial passage of the prototype (PR) cell-adapted Wyoming strain of equine infectious anemia virus (EIAV) in fetal donkey dermal (FDD) rather than fetal horse (designated fetal equine kidney [FEK]) cell cultures resulted in the generation of a variant virus strain which produced accelerated cytopathic effects in FDD cells and was 100- to 1,000-fold more sensitive to neutralizing antibodies than its parent. This neutralization-sensitive variant was designated the FDD strain. Although there were differences in glycosylation between the PR and FDD strains, passage of the FDD virus in FEK cells did not reduce its sensitivity to neutralizing antibody. Nucleotide sequencing of the region encoding the surface unit (SU) protein from the FDD strain revealed nine amino acid substitutions compared with the PR strain. Two of these substitutions resulted in changes in the polarity of charge, four caused the introduction of a charged residue, and three had no net change in charge. Nucleotide sequence analysis was extended to the region of the FDD virus genome encoding the extracellular domain of the transmembrane envelope glycoprotein (TM). Unlike the situation with the FDD virus coding region, there were minor variations in nucleotide sequence between individual molecular clones containing this region of the TM gene. Although each clone contained three nucleotide substitutions compared with the PR strain, only one of these was common to all, and this did not affect the amino acid content. Of the remaining two nucleotide substitutions, only one resulted in an amino acid change, and in each case, this change appeared to be conservative. To determine if amino acid substitutions in the SU protein of FDD cell-grown viruses were responsible for the enhanced sensitivity to neutralizing antibodies, chimeric viruses were constructed by using an infectious molecular clone of EIAV. These chimeric viruses contained all of the amino acid substitutions found in the FDD virus strain and were significantly more sensitive to neutralizing antibodies than viruses from the parental (PR) molecular clone. These results demonstrated that sensitivity to neutralizing antibodies in EIAV can be conferred by amino acid residues in the SU protein. However, such amino acid substitutions were not sufficient to enhance cytopathogenicity, as the chimeric viruses did not cause excessive degenererative effects in FDD cells, as was observed with the parental FDD virus strain.

Full Text

The Full Text of this article is available as a PDF (215.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arendrup M., Nielsen C. M., Hansen J. E., Mathiesen L. R., Lindhardt B. O., Scheibel E., Nielsen J. O. Neutralizing antibodies against two HIV-1 strains in consecutively collected serum samples: cross neutralization and association to HIV-1 related disease. Scand J Infect Dis. 1992;24(1):21–28. doi: 10.3109/00365549209048396. [DOI] [PubMed] [Google Scholar]
  2. Back N. K., Smit L., Schutten M., Nara P. L., Tersmette M., Goudsmit J. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol. 1993 Nov;67(11):6897–6902. doi: 10.1128/jvi.67.11.6897-6902.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ball J. M., Rushlow K. E., Issel C. J., Montelaro R. C. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol. 1992 Feb;66(2):732–742. doi: 10.1128/jvi.66.2.732-742.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bignon C., Martin P. M. Improved sequencing of "mini-prep" double-stranded templates using a multiwell microplate system. Biotechniques. 1992 Aug;13(2):194–198. [PubMed] [Google Scholar]
  5. Bolwell C., Parry N. R., Rowlands D. J. Comparison between in vitro neutralization titres and in vivo protection against homologous and heterologous challenge induced by vaccines prepared from two serologically distinct variants of foot-and-mouth disease virus, serotype A22. J Gen Virol. 1992 Mar;73(Pt 3):727–731. doi: 10.1099/0022-1317-73-3-727. [DOI] [PubMed] [Google Scholar]
  6. Chen C. A., Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques. 1988 Jul-Aug;6(7):632–638. [PubMed] [Google Scholar]
  7. Cook R. F., Cook S. J., Issel C. J. A nonradioactive micro-assay for released reverse transcriptase activity of a lentivirus. Biotechniques. 1992 Sep;13(3):380–386. [PubMed] [Google Scholar]
  8. Cunningham T. P., Montelaro R. C., Rushlow K. E. Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors. Gene. 1993 Feb 14;124(1):93–98. doi: 10.1016/0378-1119(93)90766-v. [DOI] [PubMed] [Google Scholar]
  9. Daar E. S., Li X. L., Moudgil T., Ho D. D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6574–6578. doi: 10.1073/pnas.87.17.6574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fujita K., Silver J., Peden K. Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1. J Virol. 1992 Jul;66(7):4445–4451. doi: 10.1128/jvi.66.7.4445-4451.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478–4482. doi: 10.1073/pnas.85.12.4478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huso D. L., Narayan O., Hart G. W. Sialic acids on the surface of caprine arthritis-encephalitis virus define the biological properties of the virus. J Virol. 1988 Jun;62(6):1974–1980. doi: 10.1128/jvi.62.6.1974-1980.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hussain K. A., Issel C. J., Schnorr K. L., Rwambo P. M., Montelaro R. C. Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies. J Virol. 1987 Oct;61(10):2956–2961. doi: 10.1128/jvi.61.10.2956-2961.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Issel C. J., Horohov D. W., Lea D. F., Adams W. V., Jr, Hagius S. D., McManus J. M., Allison A. C., Montelaro R. C. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol. 1992 Jun;66(6):3398–3408. doi: 10.1128/jvi.66.6.3398-3408.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Issel C. J., Rushlow K., Foil L. D., Montelaro R. C. A perspective on equine infectious anemia with an emphasis on vector transmission and genetic analysis. Vet Microbiol. 1988 Jul;17(3):251–286. doi: 10.1016/0378-1135(88)90069-7. [DOI] [PubMed] [Google Scholar]
  16. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768–6772. doi: 10.1073/pnas.86.17.6768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Katz J. M., Naeve C. W., Webster R. G. Host cell-mediated variation in H3N2 influenza viruses. Virology. 1987 Feb;156(2):386–395. doi: 10.1016/0042-6822(87)90418-1. [DOI] [PubMed] [Google Scholar]
  18. Kennedy-Stoskopf S., Narayan O. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence. J Virol. 1986 Jul;59(1):37–44. doi: 10.1128/jvi.59.1.37-44.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kono Y., Kobayashi K., Fukunaga Y. Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch Gesamte Virusforsch. 1973;41(1):1–10. doi: 10.1007/BF01249923. [DOI] [PubMed] [Google Scholar]
  20. Kraft R., Tardiff J., Krauter K. S., Leinwand L. A. Using mini-prep plasmid DNA for sequencing double stranded templates with Sequenase. Biotechniques. 1988 Jun;6(6):544-6, 549. [PubMed] [Google Scholar]
  21. Leonard C. K., Spellman M. W., Riddle L., Harris R. J., Thomas J. N., Gregory T. J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem. 1990 Jun 25;265(18):10373–10382. [PubMed] [Google Scholar]
  22. Letvin N. L. Immune responses in lentivirus-infected animals. Curr Opin Immunol. 1991 Aug;3(4):559–563. doi: 10.1016/0952-7915(91)90021-r. [DOI] [PubMed] [Google Scholar]
  23. Malmquist W. A., Barnett D., Becvar C. S. Production of equine infectious anemia antigen in a persistently infected cell line. Arch Gesamte Virusforsch. 1973;42(4):361–370. doi: 10.1007/BF01250717. [DOI] [PubMed] [Google Scholar]
  24. Montelaro R. C., Lohrey N., Parekh B., Blakeney E. W., Issel C. J. Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. J Virol. 1982 Jun;42(3):1029–1038. doi: 10.1128/jvi.42.3.1029-1038.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Narayan O., Clements J., Kennedy-Stoskopf S., Sheffer D., Royal W. Mechanisms of escape of visna lentiviruses from immunological control. Contrib Microbiol Immunol. 1987;8:60–76. [PubMed] [Google Scholar]
  26. Narayan O., Sheffer D., Griffin D. E., Clements J., Hess J. Lack of neutralizing antibodies to caprine arthritis-encephalitis lentivirus in persistently infected goats can be overcome by immunization with inactivated Mycobacterium tuberculosis. J Virol. 1984 Feb;49(2):349–355. doi: 10.1128/jvi.49.2.349-355.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. O'Rourke K., Perryman L. E., McGuire T. C. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus. J Gen Virol. 1988 Mar;69(Pt 3):667–674. doi: 10.1099/0022-1317-69-3-667. [DOI] [PubMed] [Google Scholar]
  28. Palker T. J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. P., Haynes B. F. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932–1936. doi: 10.1073/pnas.85.6.1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Parekh B., Issel C. J., Montelaro R. C. Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses. Virology. 1980 Dec;107(2):520–525. doi: 10.1016/0042-6822(80)90319-0. [DOI] [PubMed] [Google Scholar]
  30. Payne S. L., Fang F. D., Liu C. P., Dhruva B. R., Rwambo P., Issel C. J., Montelaro R. C. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology. 1987 Dec;161(2):321–331. doi: 10.1016/0042-6822(87)90124-3. [DOI] [PubMed] [Google Scholar]
  31. Payne S. L., Rausch J., Rushlow K., Montelaro R. C., Issel C., Flaherty M., Perry S., Sellon D., Fuller F. Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol. 1994 Feb;75(Pt 2):425–429. doi: 10.1099/0022-1317-75-2-425. [DOI] [PubMed] [Google Scholar]
  32. Perry S. T., Flaherty M. T., Kelley M. J., Clabough D. L., Tronick S. R., Coggins L., Whetter L., Lengel C. R., Fuller F. The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. J Virol. 1992 Jul;66(7):4085–4097. doi: 10.1128/jvi.66.7.4085-4097.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rasty S., Dhruva B. R., Schiltz R. L., Shih D. S., Issel C. J., Montelaro R. C. Proviral DNA integration and transcriptional patterns of equine infectious anemia virus during persistent and cytopathic infections. J Virol. 1990 Jan;64(1):86–95. doi: 10.1128/jvi.64.1.86-95.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Reitz M. S., Jr, Wilson C., Naugle C., Gallo R. C., Robert-Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell. 1988 Jul 1;54(1):57–63. doi: 10.1016/0092-8674(88)90179-1. [DOI] [PubMed] [Google Scholar]
  35. Robert-Guroff M., Brown M., Gallo R. C. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 1985 Jul 4;316(6023):72–74. doi: 10.1038/316072a0. [DOI] [PubMed] [Google Scholar]
  36. Robertson J. S., Bootman J. S., Newman R., Oxford J. S., Daniels R. S., Webster R. G., Schild G. C. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology. 1987 Sep;160(1):31–37. doi: 10.1016/0042-6822(87)90040-7. [DOI] [PubMed] [Google Scholar]
  37. Robertson J. S., Naeve C. W., Webster R. G., Bootman J. S., Newman R., Schild G. C. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology. 1985 May;143(1):166–174. doi: 10.1016/0042-6822(85)90105-9. [DOI] [PubMed] [Google Scholar]
  38. Rushlow K., Olsen K., Stiegler G., Payne S. L., Montelaro R. C., Issel C. J. Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus. Virology. 1986 Dec;155(2):309–321. doi: 10.1016/0042-6822(86)90195-9. [DOI] [PubMed] [Google Scholar]
  39. Rwambo P. M., Issel C. J., Adams W. V., Jr, Hussain K. A., Miller M., Montelaro R. C. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection. Arch Virol. 1990;111(3-4):199–212. doi: 10.1007/BF01311054. [DOI] [PubMed] [Google Scholar]
  40. Rwambo P. M., Issel C. J., Hussain K. A., Montelaro R. C. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch Virol. 1990;111(3-4):275–280. doi: 10.1007/BF01311062. [DOI] [PubMed] [Google Scholar]
  41. Salinovich O., Payne S. L., Montelaro R. C., Hussain K. A., Issel C. J., Schnorr K. L. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection. J Virol. 1986 Jan;57(1):71–80. doi: 10.1128/jvi.57.1.71-80.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sawyer L. S., Wrin M. T., Crawford-Miksza L., Potts B., Wu Y., Weber P. A., Alfonso R. D., Hanson C. V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol. 1994 Mar;68(3):1342–1349. doi: 10.1128/jvi.68.3.1342-1349.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Schild G. C., Oxford J. S., de Jong J. C., Webster R. G. Evidence for host-cell selection of influenza virus antigenic variants. Nature. 1983 Jun 23;303(5919):706–709. doi: 10.1038/303706a0. [DOI] [PubMed] [Google Scholar]
  44. Turner S., Tizard R., DeMarinis J., Pepinsky R. B., Zullo J., Schooley R., Fisher R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1335–1339. doi: 10.1073/pnas.89.4.1335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wang S. Z., Rushlow K. E., Issel C. J., Cook R. F., Cook S. J., Raabe M. L., Chong Y. H., Costa L., Montelaro R. C. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology. 1994 Feb 15;199(1):247–251. doi: 10.1006/viro.1994.1120. [DOI] [PubMed] [Google Scholar]
  46. Watkins B. A., Reitz M. S., Jr, Wilson C. A., Aldrich K., Davis A. E., Robert-Guroff M. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J Virol. 1993 Dec;67(12):7493–7500. doi: 10.1128/jvi.67.12.7493-7500.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Weiss R. A., Clapham P. R., Cheingsong-Popov R., Dalgleish A. G., Carne C. A., Weller I. V., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985 Jul 4;316(6023):69–72. doi: 10.1038/316069a0. [DOI] [PubMed] [Google Scholar]
  48. Wilson C., Reitz M. S., Jr, Aldrich K., Klasse P. J., Blomberg J., Gallo R. C., Robert-Guroff M. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol. 1990 Jul;64(7):3240–3248. doi: 10.1128/jvi.64.7.3240-3248.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Wyatt R., Thali M., Tilley S., Pinter A., Posner M., Ho D., Robinson J., Sodroski J. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol. 1992 Dec;66(12):6997–7004. doi: 10.1128/jvi.66.12.6997-7004.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES